Royalty Pharma (NASDAQ:RPRX) Stock Price Target Raised at Citigroup

Royalty Pharma (NASDAQ:RPRX) had its price objective hoisted by research analysts at Citigroup from $70.00 to $78.00 in a research report issued to clients and investors on Thursday, Benzinga reports. The firm currently has a “buy” rating on the biopharmaceutical company’s stock. Citigroup‘s price target indicates a potential upside of 15.38% from the company’s previous close.

Several other analysts have also commented on the company. JPMorgan Chase & Co. increased their price objective on Royalty Pharma from $58.00 to $62.00 and gave the company an “overweight” rating in a report on Friday, August 7th. Weiss Ratings upgraded Royalty Pharma from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, September 14th. TD Cowen upped their target price on Royalty Pharma from $65.00 to $68.00 and gave the company a “buy” rating in a research report on Tuesday, September 8th. The Goldman Sachs Group reiterated a “buy” rating and issued a $66.00 price target on shares of Royalty Pharma in a research note on Thursday, August 6th. Finally, Bank of America reiterated a “buy” rating on shares of Royalty Pharma in a research note on Wednesday, August 5th. Eight equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat.com, the company has a consensus rating of “Buy” and an average target price of $63.29.

Royalty Pharma Stock Up 0.1%

RPRX traded up $0.04 during trading on Thursday, hitting $67.60. The stock had a trading volume of 4,896,620 shares, compared to its average volume of 3,424,217. The company has a market capitalization of $38.87 billion, a PE ratio of 46.62, a PEG ratio of 1.82 and a beta of 0.37. Royalty Pharma has a twelve month low of $37.31 and a twelve month high of $69.77. The company has a debt-to-equity ratio of 0.88, a quick ratio of 2.80 and a current ratio of 2.80. The stock has a 50 day simple moving average of $60.59 and a two-hundred day simple moving average of $53.53.

Royalty Pharma (NASDAQ:RPRX) last released its quarterly earnings results on Wednesday, August 5th. The biopharmaceutical company reported $1.32 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.05. The business had revenue of $674.14 million for the quarter, compared to analyst estimates of $758.93 million. Royalty Pharma had a net margin of 32.14% and a return on equity of 30.01%. On average, research analysts predict that Royalty Pharma will post 5.29 earnings per share for the current year.

Insider Buying and Selling

In other Royalty Pharma news, EVP Marshall Urist sold 4,126 shares of the firm’s stock in a transaction on Monday, October 5th. The shares were sold at an average price of $57.10, for a total value of $235,594.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Christopher Hite sold 100,000 shares of Royalty Pharma stock in a transaction on Tuesday, September 22nd. The stock was sold at an average price of $58.53, for a total transaction of $5,853,000.00. Following the sale, the executive vice president owned 270,401 shares of the company’s stock, valued at $15,826,570.53. The trade was a 27.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 208,252 shares of company stock worth $12,324,407 in the last 90 days. 18.84% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Royalty Pharma

Several hedge funds have recently made changes to their positions in RPRX. Provenance Wealth Advisors LLC acquired a new stake in Royalty Pharma during the 3rd quarter worth about $26,000. CoreCap Advisors LLC increased its holdings in shares of Royalty Pharma by 89.2% in the second quarter. CoreCap Advisors LLC now owns 876 shares of the biopharmaceutical company’s stock valued at $49,000 after purchasing an additional 413 shares during the period. Bessemer Group Inc. increased its holdings in shares of Royalty Pharma by 34.7% in the first quarter. Bessemer Group Inc. now owns 1,094 shares of the biopharmaceutical company’s stock valued at $53,000 after purchasing an additional 282 shares during the period. Root Financial Partners LLC acquired a new position in shares of Royalty Pharma in the third quarter valued at about $62,000. Finally, IFP Advisors Inc raised its stake in shares of Royalty Pharma by 263.3% in the second quarter. IFP Advisors Inc now owns 1,188 shares of the biopharmaceutical company’s stock worth $67,000 after purchasing an additional 861 shares during the last quarter. 54.35% of the stock is owned by institutional investors and hedge funds.

Key Stories Impacting Royalty Pharma

Here are the key news stories impacting Royalty Pharma this week:

• Positive Sentiment: Royalty Pharma raised its 2026 royalty-receipts outlook to $3.55 billion, a key positive that signals stronger expected cash flows from its royalty portfolio. Royalty Pharma Q3 Results Show Growth; Raises FY26 Receipts Outlook To $3.55 Bln
• Positive Sentiment: On an adjusted basis, Q3 earnings were reported at $1.21 per share, above the Zacks consensus estimate of $1.18 and up from $1.17 a year earlier. This suggests underlying earnings growth and may support investor confidence. Royalty Pharma Q3 Earnings and Revenues Surpass Estimates
• Neutral Sentiment: Q3 revenue was reported at about $690 million, but estimates cited by outlets differ: some reported a beat, while another comparison showed revenue below expectations. The conflicting benchmarks make the revenue takeaway less clear. Royalty Pharma reports third quarter 2026 results
• Negative Sentiment: A separate report put quarterly EPS at $0.32, well below its $1.18 consensus estimate. This likely reflects a different, reported accounting measure than the adjusted $1.21 figure, but could still concern investors focused on GAAP results. Royalty Pharma quarterly earnings results

Royalty Pharma Company Profile

Royalty Pharma plc (NASDAQ:RPRX) is a biopharmaceutical royalty investment company that provides funding to life sciences companies, academic institutions, and other organizations in exchange for rights to future payments tied to approved or development-stage medicines. Its business model gives innovators access to capital while allowing Royalty Pharma to participate in the long-term commercial success of pharmaceutical products.

The company acquires and manages royalty interests across a broad range of therapeutic areas, including immunology, oncology, neuroscience, rare diseases, and infectious diseases.